Cargando…
Improvement of different vaccine delivery systems for cancer therapy
Cancer vaccines are the promising tools in the hands of the clinical oncologist. Many tumor-associated antigens are excellent targets for immune therapy and vaccine design. Optimally designed cancer vaccines should combine the best tumor antigens with the most effective immunotherapy agents and/or d...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024302/ https://www.ncbi.nlm.nih.gov/pubmed/21211062 http://dx.doi.org/10.1186/1476-4598-10-3 |
_version_ | 1782196757312045056 |
---|---|
author | Bolhassani, Azam Safaiyan, Shima Rafati, Sima |
author_facet | Bolhassani, Azam Safaiyan, Shima Rafati, Sima |
author_sort | Bolhassani, Azam |
collection | PubMed |
description | Cancer vaccines are the promising tools in the hands of the clinical oncologist. Many tumor-associated antigens are excellent targets for immune therapy and vaccine design. Optimally designed cancer vaccines should combine the best tumor antigens with the most effective immunotherapy agents and/or delivery strategies to achieve positive clinical results. Various vaccine delivery systems such as different routes of immunization and physical/chemical delivery methods have been used in cancer therapy with the goal to induce immunity against tumor-associated antigens. Two basic delivery approaches including physical delivery to achieve higher levels of antigen production and formulation with microparticles to target antigen-presenting cells (APCs) have demonstrated to be effective in animal models. New developments in vaccine delivery systems will improve the efficiency of clinical trials in the near future. Among them, nanoparticles (NPs) such as dendrimers, polymeric NPs, metallic NPs, magnetic NPs and quantum dots have emerged as effective vaccine adjuvants for infectious diseases and cancer therapy. Furthermore, cell-penetrating peptides (CPP) have been known as attractive carrier having applications in drug delivery, gene transfer and DNA vaccination. This review will focus on the utilization of different vaccine delivery systems for prevention or treatment of cancer. We will discuss their clinical applications and the future prospects for cancer vaccine development. |
format | Text |
id | pubmed-3024302 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-30243022011-01-21 Improvement of different vaccine delivery systems for cancer therapy Bolhassani, Azam Safaiyan, Shima Rafati, Sima Mol Cancer Review Cancer vaccines are the promising tools in the hands of the clinical oncologist. Many tumor-associated antigens are excellent targets for immune therapy and vaccine design. Optimally designed cancer vaccines should combine the best tumor antigens with the most effective immunotherapy agents and/or delivery strategies to achieve positive clinical results. Various vaccine delivery systems such as different routes of immunization and physical/chemical delivery methods have been used in cancer therapy with the goal to induce immunity against tumor-associated antigens. Two basic delivery approaches including physical delivery to achieve higher levels of antigen production and formulation with microparticles to target antigen-presenting cells (APCs) have demonstrated to be effective in animal models. New developments in vaccine delivery systems will improve the efficiency of clinical trials in the near future. Among them, nanoparticles (NPs) such as dendrimers, polymeric NPs, metallic NPs, magnetic NPs and quantum dots have emerged as effective vaccine adjuvants for infectious diseases and cancer therapy. Furthermore, cell-penetrating peptides (CPP) have been known as attractive carrier having applications in drug delivery, gene transfer and DNA vaccination. This review will focus on the utilization of different vaccine delivery systems for prevention or treatment of cancer. We will discuss their clinical applications and the future prospects for cancer vaccine development. BioMed Central 2011-01-07 /pmc/articles/PMC3024302/ /pubmed/21211062 http://dx.doi.org/10.1186/1476-4598-10-3 Text en Copyright ©2011 Bolhassani et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<url>http://creativecommons.org/licenses/by/2.0</url>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Bolhassani, Azam Safaiyan, Shima Rafati, Sima Improvement of different vaccine delivery systems for cancer therapy |
title | Improvement of different vaccine delivery systems for cancer therapy |
title_full | Improvement of different vaccine delivery systems for cancer therapy |
title_fullStr | Improvement of different vaccine delivery systems for cancer therapy |
title_full_unstemmed | Improvement of different vaccine delivery systems for cancer therapy |
title_short | Improvement of different vaccine delivery systems for cancer therapy |
title_sort | improvement of different vaccine delivery systems for cancer therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024302/ https://www.ncbi.nlm.nih.gov/pubmed/21211062 http://dx.doi.org/10.1186/1476-4598-10-3 |
work_keys_str_mv | AT bolhassaniazam improvementofdifferentvaccinedeliverysystemsforcancertherapy AT safaiyanshima improvementofdifferentvaccinedeliverysystemsforcancertherapy AT rafatisima improvementofdifferentvaccinedeliverysystemsforcancertherapy |